NCT04444141

A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell Lymphoma

A Multicenter, Open-label, Phase Ib/II Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Subjects With Relapsed or Refractory Peripheral T Cell Lymphoma

• Status: Terminated
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: Akeso · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of AK104，an anti- PD-1 and CTLA-4 bispecific antibody, in subjects with relapsed or refractory peripheral T cell lymphoma. The subject will receive AK104 450mg Q2W until unacceptable toxicity, confirmed disease progression, withdrawal of consent, or for a maximum of 24 months.

Conditions

• Peripheral T-cell Lymphoma

Interventions

Type	Name	Description
BIOLOGICAL	AK104	The subjects will receive AK104 till disease progression or for a maximum of 24 months.

Timeline

• Start date: 2020-05-15
• Primary completion: 2022-09-30
• Completion: 2022-09-30
• First posted: 2020-06-23
• Last updated: 2022-10-19

Locations

1 site across 1 country: China